ARTICLES

Hundreds Die Every Year From Chemotherapy Overdoses Because Doctors Don't Order Simple Gene Test

Hundreds of cancer patients every year die excruciating deaths from overdoses of common chemotherapy drugs because doctors rarely order a simple gene test — required by European health agencies but not the FDA — that could identify those at risk.

By **KFF Health News**

Miss a day, miss a lot. Subscribe to The Defender's Top News of the Day. **It's free.**

By Arthur Allen

One January morning in 2021, Carol Rosen took a standard treatment for metastatic breast cancer. Three grueling weeks later, she died in excruciating pain from the very drug meant to prolong her life.

Rosen, a 70-year-old retired schoolteacher, passed her final days in anguish, enduring severe diarrhea and nausea so intense that even her mouth had to be kept from eating, drinking and eventually speaking. Skin peeled off her body. Her kidneys and liver failed.

"Your body burns from the inside out," said Rosen's daughter, Nancy Lehman, of Andover, Massachusetts.

Rosen was one of more than 275,000 cancer patients in the U.S. who are infused each year with fluorouracil, known as 5-FU, or its Rosen's case, take a nearly identical drug or pill form called capecitabine.

These common types of chemotherapy are no picnic for anyone, but for patients who are deficient in an enzyme that metabolizes fluorouracil, they can be deadly.

Those patients essentially overdose because the drugs stay in the body for hours rather than being quickly metabolized and eliminated.

The drugs kill an estimated 1 in 1,000 patients who take them — hundreds each year — and severely sicken or disable thousands more.

Doctors can test for the deficiency and get results within a week — and then either switch drugs or lower the drug's dosage to avoid the severe toxicity it carries risk.

Yet a recent survey found that only 3% of U.S. oncologists routinely order the tests before dosing patients with 5-FU or capecitabine.

That's because the most widely followed U.S. cancer treatment guidelines — issued by the National Comprehensive Cancer Network — don't recommend preemptive testing.

The U.S. Food and Drug Administration (FDA) added new warnings about the lethal risks of 5-FU to the drug's label on March 21 following pressure from KFF Health News and others. However, it also rejected requests to require the test before prescribing the chemotherapy.

The FDA's decision was based on a panel of laboratory testing was the subject of a U.S. House of Representatives hearing, also on March 21, has said it could not endorse the 5-FU toxicity tests because it never reviewed them.

But the FDA at present does not review most diagnostic tests, said Daniel Herzig, an associate professor at the University of Michigan College of Pharmacy.

For years, while other doctors and pharmacists, he has petitioned the FDA to put a black-box warning on the drug's label urging prescribers to test for the deficiency.

"FDA has responsibility to assure that drugs are used safely and effectively," he said.

The failure to warn, he said, "is an abdication of their responsibility."

The update is "a small step in the right direction, but not the sea change we need," he said.

RFK Jr. and Brian Hooker's New Book: "Vax-Unvax"

Europe stood on safety

British and European Union drug authorities have recommended the testing since 2020.

A small but growing number of U.S. hospital systems, professional groups and health advocates, including the American Cancer Society, also endorse routine testing.

Most U.S. insurers, private and public, will cover the tests, which Medicare reimburses for $175, although tests may cost more depending on how many variants they screen for.

It think it's the intransigence of doctors sitting on these panels, the mindset of they are oncologists, drugs are our tools, we don't want to put barriers to reasons not to use our tools," said Gabriel Brooks, an oncologist and researcher at the Dartmouth Cancer Center.

Brooks is the intransigence of doctors sitting on these panels, the mindset of they are oncologists, drugs are our tools, we don't want to put barriers to reasons not to use our tools," said Gabriel Brooks, an oncologist and researcher at the Dartmouth Cancer Center.

In states' guidelines on colon cancer, the Cancer Network panel noted that most oncologists in the U.S. now give cancer patients drugs such as 5-FU and capecitabine for patients carrying such a variant could stem from of a cure or remission.

Many doctors on the panel, including the University of Colorado oncologist Wells Messersmith, have said they have never witnessed a 5-FU death.

In European hospitals, the practice is to start patients with a half- or quarter-dose of 5-FU if tests show a patient is a poor metabolizer, then up the dose if the patient responds well to the drug.

Advocates for the approach say American oncology leaders are dragging their feet unnecessarily, and harming people in the process.

"I think it's the intransigence of people